Fennec Total Revenue vs Interest Expense Analysis

FENC Stock

USD 6.84 0.28 3.93%

Fennec Pharmaceuticals financial indicator trend analysis is much more than just examining Fennec Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fennec Pharmaceuticals is a good investment. Please check the relationship between Fennec Pharmaceuticals Total Revenue and its Interest Expense accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fennec Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.

Total Revenue vs Interest Expense

Total Revenue vs Interest Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fennec Pharmaceuticals Total Revenue account and Interest Expense. At this time, the significance of the direction appears to have totally related.

The correlation between Fennec Pharmaceuticals' Total Revenue and Interest Expense is 0.99. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Interest Expense in the same time period over historical financial statements of Fennec Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Fennec Pharmaceuticals' Total Revenue and Interest Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Fennec Pharmaceuticals are associated (or correlated) with its Interest Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Expense has no effect on the direction of Total Revenue i.e., Fennec Pharmaceuticals' Total Revenue and Interest Expense go up and down completely randomly.

Correlation Coefficient

0.99

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Revenue

Total revenue comprises all receipts Fennec Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Most indicators from Fennec Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fennec Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fennec Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.At present, Fennec Pharmaceuticals' Enterprise Value is projected to increase significantly based on the last few years of reporting.

Fennec Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Retained Earnings Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		0.43	-0.18	0.15	0.5	-0.19	0.62	0.34	-0.38	-0.69	0.6	0.95	0.03	0.27	0.48	0.51	0.96	0.3	0.77	-0.69	0.81	0.45	0.3	0.63	0.39	0.34
Short Long Term Debt Total	0.43		0.22	0.71	-0.53	-0.73	-0.39	0.63	0.65	-0.78	0.92	0.19	0.02	0.18	-0.15	0.98	0.2	0.9	0.68	-0.48	0.69	0.99	0.83	0.45	0.99	0.63
Other Current Liab	-0.18	0.22		0.8	-0.5	-0.02	-0.46	0.27	0.36	-0.13	0.06	-0.27	-0.25	-0.13	-0.2	0.14	-0.27	0.2	-0.14	0.46	-0.11	0.17	0.14	0.12	0.31	0.27
Total Current Liabilities	0.15	0.71	0.8		-0.58	-0.43	-0.45	0.57	0.57	-0.53	0.63	-0.03	-0.15	0.01	-0.16	0.67	-0.02	0.7	0.33	0.06	0.35	0.68	0.65	0.28	0.78	0.57
Total Stockholder Equity	0.5	-0.53	-0.5	-0.58		0.55	0.97	-0.17	-0.97	0.08	-0.29	0.7	-0.05	0.06	0.62	-0.45	0.69	-0.55	0.11	-0.26	0.12	-0.52	-0.47	0.13	-0.58	-0.17
Other Liab	-0.19	-0.73	-0.02	-0.43	0.55		0.47	0.05	-0.66	0.24	-0.7	0.01	-0.41	-0.15	0.23	-0.77	0.0	-0.7	-0.27	0.1	-0.28	-0.79	-0.66	0.15	-0.77	0.05
Net Tangible Assets	0.62	-0.39	-0.46	-0.45	0.97	0.47		-0.04	-0.92	-0.06	-0.11	0.77	-0.11	0.02	0.63	-0.3	0.77	-0.36	0.28	-0.35	0.26	-0.37	-0.28	0.21	-0.43	-0.04
Property Plant And Equipment Net	0.34	0.63	0.27	0.57	-0.17	0.05	-0.04		0.24	-0.82	0.57	0.24	-0.47	0.02	0.01	0.56	0.25	0.59	0.68	-0.54	0.68	0.55	0.53	0.72	0.57	1.0
Net Debt	-0.38	0.65	0.36	0.57	-0.97	-0.66	-0.92	0.24		-0.18	0.45	-0.61	0.05	-0.07	-0.6	0.59	-0.6	0.69	0.04	0.11	0.02	0.65	0.63	-0.09	0.68	0.24
Retained Earnings	-0.69	-0.78	-0.13	-0.53	0.08	0.24	-0.06	-0.82	-0.18		-0.77	-0.54	0.12	-0.31	-0.17	-0.78	-0.55	-0.62	-0.91	0.78	-0.95	-0.75	-0.57	-0.86	-0.73	-0.82
Accounts Payable	0.6	0.92	0.06	0.63	-0.29	-0.7	-0.11	0.57	0.45	-0.77		0.38	0.13	0.27	0.06	0.96	0.39	0.9	0.77	-0.56	0.79	0.93	0.88	0.42	0.91	0.57
Cash	0.95	0.19	-0.27	-0.03	0.7	0.01	0.77	0.24	-0.61	-0.54	0.38		0.05	0.29	0.58	0.28	1.0	0.04	0.65	-0.63	0.7	0.21	0.05	0.54	0.15	0.24
Non Current Assets Total	0.03	0.02	-0.25	-0.15	-0.05	-0.41	-0.11	-0.47	0.05	0.12	0.13	0.05		0.82	0.01	0.12	0.05	-0.12	-0.07	-0.02	0.01	0.09	-0.12	-0.2	0.04	-0.47
Non Currrent Assets Other	0.27	0.18	-0.13	0.01	0.06	-0.15	0.02	0.02	-0.07	-0.31	0.27	0.29	0.82		0.2	0.24	0.29	-0.07	0.27	-0.36	0.37	0.19	-0.11	0.33	0.15	0.02
Other Assets	0.48	-0.15	-0.2	-0.16	0.62	0.23	0.63	0.01	-0.6	-0.17	0.06	0.58	0.01	0.2		-0.08	0.57	-0.22	0.27	-0.3	0.28	-0.16	-0.18	0.23	-0.2	0.01
Long Term Debt	0.51	0.98	0.14	0.67	-0.45	-0.77	-0.3	0.56	0.59	-0.78	0.96	0.28	0.12	0.24	-0.08		0.29	0.9	0.73	-0.52	0.75	0.99	0.85	0.42	0.97	0.56
Cash And Short Term Investments	0.96	0.2	-0.27	-0.02	0.69	0.0	0.77	0.25	-0.6	-0.55	0.39	1.0	0.05	0.29	0.57	0.29		0.05	0.66	-0.64	0.7	0.22	0.06	0.54	0.16	0.25
Net Receivables	0.3	0.9	0.2	0.7	-0.55	-0.7	-0.36	0.59	0.69	-0.62	0.9	0.04	-0.12	-0.07	-0.22	0.9	0.05		0.59	-0.33	0.56	0.91	0.98	0.25	0.91	0.59
Common Stock Total Equity	0.77	0.68	-0.14	0.33	0.11	-0.27	0.28	0.68	0.04	-0.91	0.77	0.65	-0.07	0.27	0.27	0.73	0.66	0.59		-0.88	0.95	0.68	0.58	0.73	0.64	0.68
Retained Earnings Total Equity	-0.69	-0.48	0.46	0.06	-0.26	0.1	-0.35	-0.54	0.11	0.78	-0.56	-0.63	-0.02	-0.36	-0.3	-0.52	-0.64	-0.33	-0.88		-0.87	-0.48	-0.32	-0.73	-0.38	-0.54
Common Stock Shares Outstanding	0.81	0.69	-0.11	0.35	0.12	-0.28	0.26	0.68	0.02	-0.95	0.79	0.7	0.01	0.37	0.28	0.75	0.7	0.56	0.95	-0.87		0.7	0.55	0.77	0.65	0.68
Non Current Liabilities Total	0.45	0.99	0.17	0.68	-0.52	-0.79	-0.37	0.55	0.65	-0.75	0.93	0.21	0.09	0.19	-0.16	0.99	0.22	0.91	0.68	-0.48	0.7		0.84	0.39	0.99	0.55
Other Current Assets	0.3	0.83	0.14	0.65	-0.47	-0.66	-0.28	0.53	0.63	-0.57	0.88	0.05	-0.12	-0.11	-0.18	0.85	0.06	0.98	0.58	-0.32	0.55	0.84		0.19	0.85	0.53
Other Stockholder Equity	0.63	0.45	0.12	0.28	0.13	0.15	0.21	0.72	-0.09	-0.86	0.42	0.54	-0.2	0.33	0.23	0.42	0.54	0.25	0.73	-0.73	0.77	0.39	0.19		0.38	0.72
Total Liab	0.39	0.99	0.31	0.78	-0.58	-0.77	-0.43	0.57	0.68	-0.73	0.91	0.15	0.04	0.15	-0.2	0.97	0.16	0.91	0.64	-0.38	0.65	0.99	0.85	0.38		0.57
Property Plant And Equipment Gross	0.34	0.63	0.27	0.57	-0.17	0.05	-0.04	1.0	0.24	-0.82	0.57	0.24	-0.47	0.02	0.01	0.56	0.25	0.59	0.68	-0.54	0.68	0.55	0.53	0.72	0.57

Click cells to compare fundamentals

Fennec Pharmaceuticals Account Relationship Matchups

Fennec Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.1M	31.4M	22.4M	26.9M	26.7M	16.1M
Other Current Liab	659K	776K	877K	2.2M	3.8M	2.1M
Total Current Liabilities	2.3M	2.3M	1.7M	4.6M	7.5M	7.9M
Total Stockholder Equity	11.9M	29.1M	15.8M	(2.6M)	(11.6M)	(11.0M)
Net Tangible Assets	11.9M	29.1M	15.8M	(2.6M)	(3.0M)	(2.8M)
Net Debt	(13.7M)	(30.3M)	(16.1M)	1.1M	16.4M	17.2M
Retained Earnings	(144.0M)	(162.1M)	(179.5M)	(203.2M)	(218.1M)	(207.2M)
Accounts Payable	1.6M	1.6M	777K	2.4M	3.8M	3.9M
Cash	13.7M	30.3M	21.1M	23.8M	13.2M	11.0M
Other Assets	262K	1.1M	27K	211K	(0.3)	(0.28)
Cash And Short Term Investments	13.7M	30.3M	21.1M	23.8M	13.2M	11.7M
Retained Earnings Total Equity	(131.3M)	(144.0M)	(162.1M)	(179.5M)	(161.5M)	(153.5M)
Common Stock Shares Outstanding	19.9M	23.7M	26.0M	26.3M	26.6M	27.9M
Liabilities And Stockholders Equity	14.1M	31.4M	22.4M	26.9M	26.7M	16.1M
Non Current Liabilities Total	1.6M	1.6M	5.0M	24.9M	30.8M	32.3M
Other Current Assets	234K	276K	253K	63K	2.6M	2.7M
Other Stockholder Equity	48.3M	49.2M	53.2M	56.8M	61.8M	38.1M
Total Liab	2.3M	2.3M	6.6M	29.5M	38.3M	40.2M
Total Current Assets	13.9M	31.4M	22.4M	26.7M	26.7M	28.1M
Capital Surpluse	44.9M	48.3M	49.2M	53.2M	61.2M	49.4M
Net Invested Capital	11.9M	29.1M	20.8M	22.3M	19.3M	17.3M
Net Working Capital	11.6M	29.1M	20.7M	22.1M	19.3M	17.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether Fennec Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fennec Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fennec Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fennec Pharmaceuticals Stock:

How To Invest In Fennec

Details

Is Fennec Stock a good investment?

Details

What is Fennec Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fennec Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.

You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Fennec Stock analysis

When running Fennec Pharmaceuticals' price analysis, check to measure Fennec Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fennec Pharmaceuticals is operating at the current time. Most of Fennec Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Fennec Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fennec Pharmaceuticals' price. Additionally, you may evaluate how the addition of Fennec Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world

Is Fennec Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.60)

Revenue Per Share

1.684

Quarterly Revenue Growth

14.132

Return On Assets

0.0857

Return On Equity

(10.06)

The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Fennec Total Revenue vs Interest Expense Analysis

Total Revenue vs Interest Expense

Total Revenue vs Interest Expense Correlation Analysis

Correlation Coefficient

Total Revenue

Interest Expense

Fennec Pharmaceuticals fundamental ratios Correlations

Fennec Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Fennec Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Fennec Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.99	Long Term Debt
Total Liab	+ 0.99	Non Current Liabilities Total

Net Debt	- 0.97	Total Stockholder Equity
Common Stock Shares Outstanding	- 0.95	Retained Earnings
Net Debt	- 0.92	Net Tangible Assets
Common Stock Total Equity	- 0.91	Retained Earnings
Retained Earnings Total Equity	- 0.88	Common Stock Total Equity
Common Stock Shares Outstanding	- 0.87	Retained Earnings Total Equity